Sowell Financial Services LLC Buys 3,985 Shares of AbbVie Inc. $ABBV

Sowell Financial Services LLC grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 9.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 48,301 shares of the company’s stock after purchasing an additional 3,985 shares during the quarter. Sowell Financial Services LLC’s holdings in AbbVie were worth $12,635,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Lifelong Wealth Advisors Inc. grew its position in shares of AbbVie by 2.1% in the 3rd quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company’s stock valued at $459,000 after buying an additional 36 shares during the last quarter. James T. Borello RIA raised its stake in AbbVie by 3.5% during the 3rd quarter. James T. Borello RIA now owns 1,192 shares of the company’s stock worth $312,000 after acquiring an additional 40 shares in the last quarter. ACT Advisors LLC. raised its stake in AbbVie by 2.5% during the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after acquiring an additional 41 shares in the last quarter. Willner & Heller LLC lifted its position in AbbVie by 0.7% in the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock valued at $1,472,000 after acquiring an additional 43 shares during the last quarter. Finally, B.O.S.S. Retirement Advisors LLC lifted its position in AbbVie by 3.1% in the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock valued at $359,000 after acquiring an additional 43 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $284.63 on Thursday. The company has a 50-day simple moving average of $264.93 and a 200-day simple moving average of $240.92. AbbVie Inc. has a one year low of $190.75 and a one year high of $291.40. The stock has a market capitalization of $502.89 billion, a price-to-earnings ratio of 80.41, a PEG ratio of 1.32 and a beta of 0.24.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the business earned $2.97 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts forecast that AbbVie Inc. will post 13.94 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. AbbVie’s payout ratio is presently 195.48%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ABBV. Leerink Partners upped their price objective on shares of AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. HSBC raised their price objective on AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. UBS Group lifted their target price on AbbVie from $260.00 to $275.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 6th. Weiss Ratings raised AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Finally, Piper Sandler upped their target price on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $278.07.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported encouraging Phase 2a data for ABBV-466, an investigational combination treatment for Crohn’s disease. The therapy reportedly outperformed Skyrizi alone, strengthening the company’s immunology pipeline and helping offset concerns about the eventual loss of exclusivity for Humira. AbbVie’s Crohn’s Combo Topped Skyrizi Alone in a Phase 2a Trial
• Positive Sentiment: Allergan Aesthetics, AbbVie’s aesthetics business, presented new and long-term evidence for HArmonyCa, JUVÉDERM, SKINVIVE and BOTOX Cosmetic. Continued product adoption and clinical support could aid growth in the aesthetics segment. Allergan Aesthetics Deepens Science Behind Multimodal Approach
• Positive Sentiment: The company launched a multiyear partnership with McLaren Racing, including the “AbbVie Race to Innovate” patient-advocacy campaign. The agreement is primarily a branding initiative, but it may increase awareness of AbbVie’s immunology franchise. McLaren Racing Announces Partnership With AbbVie
• Neutral Sentiment: Analyst comparisons continue to highlight AbbVie’s revenue growth, strong free cash flow and dependable dividend increases. However, the stock’s elevated valuation after its rally leaves less room for disappointment.
• Negative Sentiment: AbbVie halted a Phase 1b combination trial for early-stage liver cancer. Because the study was in an early development stage, the direct financial impact may be limited, but the decision removes a potential pipeline opportunity and likely weighed on sentiment. AbbVie Halts Early-Stage Liver Cancer Combo Trial

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is owned by company insiders.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.